Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin

Table 2 Eradication of Mycoplasma genitalium DNA during treatment with josamycin in 46 males with urethritis

Bacterial load pre-treatment	M. genitaliumDNA concentration (geq/mL [log₁₀])	No. (%) ofM. genitaliumpositive patients
Bacterial load pre-treatment	M. genitaliumDNA concentration (geq/mL [log₁₀])	0 d/t	3 d/t	8 d/t	2 d/at	10-14 d/at
Low	≤4	10 (100)	3 (30)	0 (0)	0 (0)	0 (0)
Moderate	>4 - <6	29 (100)	15 (51.7)^b	3 (10.3)	2 (6.9)^d	0 (0)
High	≥6	6 (100)	5 (83.3)	2 (33.3)^c	3 (50)	3 (50)
Total no. of patients examined		45^a	45	45	45	14^e

geq/mL (log₁₀), log₁₀ of genome equivalents/mL; d/t, days of treatment; d/at, days after completed treatment.
^aSample from one patient was not available. At 3 d/t, this patient had 3.1 geq/mL [log₁₀], and at the three subsequent visits he was M. genitalium negative.
^bSample from one patient was not available. This patient was asymptomatic, M. genitalium negative but demonstrated microscopic signs of urethritis on the three subsequent visits.
^cSample from one patient was not available. This was treatment failure A, see Table 3.
^dSample from one patient was not available. The patient reported to be asymptomatic on the phone and at 3 d/t and 8 d/t, no symptoms, signs or M. genitalium DNA was detected.
^eThirty-two patients did not attend. However, all of the non-attending patients were M. genitalium negative already at earlier visits (both at 8 d/t and 2 d/at) and also reported to be completely asymptomatic on phone.

ISSN: 1471-2334